Lukas Scheibler - 28 Jan 2022 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)

Reporting relationship: CHIEF INNOVATION OFFICER
Issuer ticker: APLS
Reported as of: 28 Jan 2022
Net transaction value: -$72,208
SEC form: 4
Accepted by SEC: 01 Feb 2022, 16:58:09 UTC
Prior SEC filing: 24 Jan 2022
Next SEC filing: 10 Feb 2022
Source filing: View source filing
Reporting owner signature: /s/ David Watson, attorney-in-fact for Lukas Scheibler

Key filing fact

Lukas Scheibler filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 01 Feb 2022.

Key facts

This page summarizes Lukas Scheibler's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 01 Feb 2022, 16:58.

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

Shares, units, or other non-derivative securities reported in this filing.

APLS transaction

Tax liability

APLS transaction

Sale

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Explanation of responses 2 footnotes

Footnote F1

This represents shares used to cover tax withholding on a Restricted Stock Unit release.

Footnote F2

This is a scheduled sale from 10B5-1 trading plan.